Merck To Allow Sinopharm To Sell Covid Drug In China

By Brooks M. Deering, The Chicago Times

September 29, 2022

NEW YORK — Merck & Co announced on Wednesday that it will allow China based Sinopharm to distribute and import Merck’s COVID-19 antiviral drug molnupiravir in China, pending approval by the Chinese government.

In a statement, Merck said it reached a cooperation framework agreement that grants Sinopharm  distribution and exclusive import rights of the medicine on the Chinese mainland.  In addition, Merck agreed to allow Sinopharm’s affiliate, China National Biotec Group, to manufacture the drug under a transfer technology agreement.